Breaking News - The Fly

Open Search

VIRX

Viracta Therapeutics

$

()

Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial

VIRX

4/15/2024 - 08:15am

Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)

VIRX

3/7/2024 - 16:41pm

Viracta announces completion of second-stage enrollment in NAVAL-1 trial

VIRX

2/29/2024 - 08:18am

Oppenheimer biotech/healthcare analysts hold analyst/industry conference call

VIRX

2/15/2024 - 12:25pm

Oppenheimer biotech/healthcare analysts hold analyst/industry conference call

VIRX

2/15/2024 - 04:55am

Oppenheimer biotech/healthcare analysts hold analyst/industry conference call

VIRX

2/13/2024 - 17:12pm

Viracta Therapeutics price target lowered by $6 at H.C. Wainwright

VIRX

1/5/2024 - 06:11am

Viracta Therapeutics provides anticipated 2024 milestones

VIRX

1/4/2024 - 08:24am

Viracta Therapeutics announces ODD granted by U.S. FDA to nana-val

VIRX

12/12/2023 - 08:02am

Viracta Therapeutics granted orphan status for carcinoma treatment

VIRX

12/11/2023 - 09:57am

Viracta Therapeutics announces interim data from Phase 1b/2 trial of nana-val

VIRX

12/4/2023 - 08:33am

Viracta Therapeutics reports Q3 EPS (33c), consensus (30c)

VIRX

11/9/2023 - 08:31am

Viracta Therapeutics to host R&D Day highlighting Nana-val

VIRX

10/4/2023 - 07:13am

Viracta Therapeutics price target lowered to $5 from $10 at SVB Securities

VIRX

8/15/2023 - 08:26am

Viracta Therapeutics expects cash to fund operations into late 2024

VIRX

8/14/2023 - 08:13am